Table 1. Open in new tab A List of...

Statements

Do you have expertise in this biomarker?

Would you recommend this as an appropriate biomarker of aging for use in intervention studies?

Statements

Suitable as an outcome for acute intervention studies?
Suitable as an outcome for short-term intervention (<3 months) studies?
Suitable as an outcome for medium-term intervention (3–6 months) studies?
Suitable as an outcome for long-term intervention (≥6 months) studies?
Suitable for field settings?
Suitable for cognitively impaired participants?
Suitable for frail participants?
Does the act of measuring this biomarker accelerate aging?
Is it clinically validated (ie, has it been validated for use in clinical settings against set clinical standards)?
Is it mechanistically validated (ie, does the biomarker reflect underlying cellular and molecular mechanisms of aging)?
Is it generalizable (ie, does the biomarker function across different applications, eg, cell type, organ, system, human populations)?
Is it precise (ie, repeatable, and reproducible)?
Is it reliable (ie, repeatable with minimal technical variability)?
Are sampling and source materials easily obtained including collection, storage, and processing?
Are complex models or software required for interpretation?
Is it sensitive?
Is it specific?
Can it be blinded to participants?
Can it be blinded to researchers?
Can it be blinded to data analysts?
Does it predict functional aspects of aging better than chronological aging?
Is it responsive (ie, does it respond to accelerated or decelerated aging)?
Is this biomarker of...

Minimal burden

Moderate burden

Burdensome

24. Is this biomarker...

Noninvasive

Moderately invasive

Invasive

25. Is this biomarker of...

Minimal financial cost (<$10/participant)

Low financial cost ($10–50/participant)

Moderate financial cost ($51–100/participant)

High financial cost ($101–1000+/participant)

Table 1.

Open in new tab

A List of Statements (Referred to Here as “Statements”) Provided to Panel Members for Each Biomarker in Round 2 and Round 3 (When Required)

Statements
Do you have expertise in this biomarker?
Would you recommend this as an appropriate biomarker of aging for use in intervention studies?
Statements
Suitable as an outcome for acute intervention studies? Suitable as an outcome for short-term intervention (<3 months) studies? Suitable as an outcome for medium-term intervention (3–6 months) studies? Suitable as an outcome for long-term intervention (≥6 months) studies? Suitable for field settings? Suitable for cognitively impaired participants? Suitable for frail participants? Does the act of measuring this biomarker accelerate aging? Is it clinically validated (ie, has it been validated for use in clinical settings against set clinical standards)? Is it mechanistically validated (ie, does the biomarker reflect underlying cellular and molecular mechanisms of aging)? Is it generalizable (ie, does the biomarker function across different applications, eg, cell type, organ, system, human populations)? Is it precise (ie, repeatable, and reproducible)? Is it reliable (ie, repeatable with minimal technical variability)? Are sampling and source materials easily obtained including collection, storage, and processing? Are complex models or software required for interpretation? Is it sensitive? Is it specific? Can it be blinded to participants? Can it be blinded to researchers? Can it be blinded to data analysts? Does it predict functional aspects of aging better than chronological aging? Is it responsive (ie, does it respond to accelerated or decelerated aging)? Is this biomarker of...
Minimal burden
Moderate burden
Burdensome
24. Is this biomarker...
Noninvasive
Moderately invasive
Invasive
25. Is this biomarker of...
Minimal financial cost (<$10/participant)
Low financial cost ($10–50/participant)
Moderate financial cost ($51–100/participant)
High financial cost ($101–1000+/participant)

Statements
Do you have expertise in this biomarker?
Would you recommend this as an appropriate biomarker of aging for use in intervention studies?
Statements
Suitable as an outcome for acute intervention studies? Suitable as an outcome for short-term intervention (<3 months) studies? Suitable as an outcome for medium-term intervention (3–6 months) studies? Suitable as an outcome for long-term intervention (≥6 months) studies? Suitable for field settings? Suitable for cognitively impaired participants? Suitable for frail participants? Does the act of measuring this biomarker accelerate aging? Is it clinically validated (ie, has it been validated for use in clinical settings against set clinical standards)? Is it mechanistically validated (ie, does the biomarker reflect underlying cellular and molecular mechanisms of aging)? Is it generalizable (ie, does the biomarker function across different applications, eg, cell type, organ, system, human populations)? Is it precise (ie, repeatable, and reproducible)? Is it reliable (ie, repeatable with minimal technical variability)? Are sampling and source materials easily obtained including collection, storage, and processing? Are complex models or software required for interpretation? Is it sensitive? Is it specific? Can it be blinded to participants? Can it be blinded to researchers? Can it be blinded to data analysts? Does it predict functional aspects of aging better than chronological aging? Is it responsive (ie, does it respond to accelerated or decelerated aging)? Is this biomarker of...
Minimal burden
Moderate burden
Burdensome
24. Is this biomarker...
Noninvasive
Moderately invasive
Invasive
25. Is this biomarker of...
Minimal financial cost (<$10/participant)
Low financial cost ($10–50/participant)
Moderate financial cost ($51–100/participant)
High financial cost ($101–1000+/participant)

This Feature Is Available To Subscribers Only